If this study meets the primary endpoint, using avelumab in the adjuvant setting following standard chemotherapy would become the standard of care for patients with dMMR/MSI-H and/or POLE exonuclease domain mutant colon cancers. Here, POLE is linked to malignant colon neoplasm.